Royal UNIBREW A/S
COMPANY ANNOUNCEMENT NO 11/2021 – 8 MARCH 2021
On 3 March 2021, Royal Unibrew initiated a share buy-back program, cf. company announcement no. 9/2021 of 3 March 2021. The program is carried out under Art. 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (the Market Abuse Regulation - MAR) and the resulting delegated legislation. The share buy-back program is expected to be realized in the period from 4 March 2021 to 30 June 2021. The total share buy-back in the period will not exceed a market price of DKK 250 million.
The following transactions have been made under the program:
| Number of Shares | Average purchase price | Transaction value, DKK | |
| Accumulated, last announcement | 0 | - | - |
| 4 March 2021 | 3,450 | 622.53 | 2,147,724.02 |
| 5 March 2021 | 1,793 | 643.80 | 1,154,325.15 |
| Accumulated under the program | 5,243 | 629.80 | 3,302,049.17 |
With the transactions stated above Royal Unibrew owns a total of 772,683 shares, corresponding to 1.6% of the share capital. The total amount of shares in the company is 49,350,000, including treasury shares.
For further information on this Announcement:
CFO Lars Vestergaard, tel (+45) 30 93 18 08
www.royalunibrew.com
Attachments
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Genmab A/S18.10.2025 12:00:34 CEST | Press release
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
F. Hoffmann-La Roche Ltd18.10.2025 07:00:00 CEST | Press release
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
StoneX Group Inc.18.10.2025 01:12:36 CEST | Press release
StoneX Expands Wealth Management Offering for Latin American Clients
F. Hoffmann-La Roche Ltd17.10.2025 22:20:00 CEST | Press release
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Eavor Technologies Inc.17.10.2025 18:00:00 CEST | Press release
Mark Fitzgerald Appointed President and Chief Executive Officer of Eavor Technologies Inc.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom